The MVA vaccine boosts pp65-specific CD8+ T cells (and supports CMV-specific CAR T cells), which recognize pp65 peptides presented on MHC I of CMV-infected cells and kill them via perforin/granzyme-mediated cytolysis, with CD4+ T-cell help.